Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Acrivastine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH1 known ✓ | P35367 | 3/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 3/20 | 1.00 |
| ▸ | OPRK1 | P41145 | 3/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | ADRA2B | P18089 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | THPO | P40225 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | GMNN | O75496 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrivastine SCHEMBL4703 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL5053832 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9051626 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL15392862 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL4702 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL11034921 | 1.00 | ADRA1A (1.00) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL2832062 | 0.99 | ADRA1A (0.98) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9561912 | 0.98 | ADRA1A (0.96) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| Acrivastine SCHEMBL9561915 | 0.98 | ADRA1A (0.96) | ADRA1AHRH1OPRK1SLC6A4PTGS2 | |
| SCHEMBL10505907 | 0.92 | SLC6A4 (0.84) | ADRA1AHRH1OPRK1SLC6A4PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | claimed |
| EP-4247331-B1 | ORODISPERSIBLE POWDER COMPOSITION COMPRISING AN ANTIHISTAMINE COMPOUND | BIOPHARMA SYNERGIES S L (ES) | 2025-10-08 | — | — | EP | claimed |
| US-20250041208-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2025-02-06 | — | — | US | claimed |
| EP-3508501-B1 | USE OF ANTI-CGRP ANTIBODIES AND ANTIBODY FRAGMENTS TO PREVENT OR INHIBIT PHOTOPHOBIA OR LIGHT AVERSION IN SUBJECTS IN NEED THEREOF, ESPECIALLY MIGRAINE SUFFERERS | H LUNDBECK AS (DK) | 2024-11-06 | — | — | EP | claimed |
| EP-4444277-A1 | NEW INJECTABLE COMBINATION FORMULATION | Nanexa AB (SE) | 2024-10-16 | — | — | EP | claimed |
| WO-2023105227-A1 | NEW INJECTABLE COMBINATION FORMULATION | NANEXA AB (SE) | 2023-06-15 | — | — | WO | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| WO-2026100654-A1 | NUCLEIC ACID INTRODUCTION AID, NUCLEIC ACID INTRODUCTION AGENT, AND NUCLEIC ACID INTRODUCTION METHOD | 株式会社インファーマシア | 2026-05-15 | — | — | WO | disclosed |
| EP-4637713-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF DERMAL AND OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2025-10-29 | — | — | EP | disclosed |
| EP-4633602-A1 | NEW PHARMACEUTICAL COMPOSITIONS COMPRISING GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS | Nanexa AB (SE) | 2025-10-22 | — | — | EP | disclosed |
| US-20250312275-A1 | GAS PHASE DEPOSITION TECHNIQUE FOR PREPARATION OF PHARMACEUTICAL COMPOSITIONS | NANEXA AB (SE) | 2025-10-09 | — | — | US | disclosed |
| US-20250275951-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS | 2025-09-04 | — | — | US | disclosed |
| US-12377191-B2 | Chondroinductive peptides and compositions and methods of use thereof | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2025-08-05 | — | — | US | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| WO-2022192450-A2 | SELF-ASSEMBLING PEPTIDES, NANOFIBERS, AND METHODS OF USE | THE BOARD OF REGENTS OF THE UNIVERSITY OF OKLAHOMA (US) | 2022-09-15 | — | — | WO | disclosed |
| CN-115038451-A | Multimodal compositions and methods of treatment | 阿奎斯蒂弗医疗股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| US-11389453-B2 | Compositions and methods for treating chemosensory dysfunction | CYRANO THERAPEUTICS, INC. (US) | 2022-07-19 | — | — | US | disclosed |
| WO-2022094422-A9 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022094422-A1 | DRUGS TARGETING INFLAMMATION FOR THE TREATMENT OF OSTEOARTHRITIS AND OTHER INFLAMMATORY DISEASES | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2022-05-05 | — | — | WO | disclosed |
| EP-3962455-A1 | NEW PHARMACEUTICAL COMPOSITION FOR DRUG DELIVERY | Orexo AB (SE) | 2022-03-09 | — | — | EP | disclosed |